大黄酸对非酒精性脂肪肝病模型大鼠干预作用及对血清IL-1β、IL-6的影响

Effect of Rhein on Serum IL-1β and IL-6 in Rats with Non-alcoholic Fatty Liver Disease

目的观察大黄酸对非酒精性脂肪肝病(NAFLD)模型大鼠干预作用及血清白细胞介素1β(IL-1β)、白细胞介素6(IL-6)的影响。方法 SD雄性大鼠40只随机分为对照组10只,模型组20只,大黄酸组10只。采用高脂高果糖诱导建立NAFLD大鼠模型。测定大鼠体质量、肝湿重,检测比较各组大鼠血清ALT、AST、TC、TG、GLU、IL-1β、IL-6水平。结果与对照组比较,模型组大鼠肝脏细胞脂肪性病变明显,且血清ALT[(62.11±6.8)U/L比(28.22±4.2)U/L]、AST[(147.67±5.6)U/L比(100.89±2.0)U/L]、TG[(0.80±0.08)mol/L比(0.40±0.06)mol/L]、TC[(1.65±0.2)mol/L比(0.82±0.1)mol/L]、GLU[(7.44±0.5)mmol/L比(5.28±0.2)mmol/L]、IL-1β[(29.25±5.85)pg/m L比15.32±2.68)pg/m L]、IL-6[(202.64±12.78)pg/m L比(138.08±4.96)pg/m L明显增高(P均<0.05);与NAFLD模型组比较,大黄酸组大鼠肝脏细胞脂肪性病变显著改善,且血清ALT[(32.00±4.7)U/L比(62.11±6.8)U/L]、AST[(137.00±6.3)U/L比(100.89±2.0)U/L、TG[(0.55±0.14)mol/L比(0.80±0.18)mol/L、TC[(1.05±0.1)mmol/L比(1.65±0.2)mmol/L]、GLU[(5.58±0.3)mmol/L比(7.44±0.5)mmol/L]、IL-1β[(17.89±1.58)pg/m L比(29.25±5.85)pg/m L、IL-6[(105.56±11.84)pg/m L比(202.64±12.78)pg/m L]明显降低(P均<0.05)。结论大黄酸可能通过降低模型大鼠血清IL-1β、IL-6水平,改善肝脏脂质沉积和炎症水平,进而抑制肝脏脂肪变性。

Objective to study the rhein's intervention to experimental rats suffering from non-alcoholic fatty liver disease(NAFLD) and its impact on serum IL-1β and IL-6. Methods NAFLD rat model was built by making use of high fat and high fructose induction. Forty SD male rats were randomly divided into the control group(n=10), the model group(n=20) and the rhein group(n=10). The rats' physique, wet weight of liver and the level of serum ALT, AST, TC, TG, GLU, IL-1β, IL-6 were measured in all groups. Results Compared with the control group, the lever cells of rats in the model group showed obvious fatty lesion, and the serum ALT(62.11±6.8 U/L vs28.22±4.2 U/L), AST(147.67±5.6 U/L vs 100.89±2.0), TG(0.80±0.08 mol/L vs 0.40±0.06 mol/L), TC(1.65±0.2 mol/L vs0.82±0.1 mol/L), GLU(7.44±0.5 mmol/L vs 5.28±0.2 mmol/L), IL-1β(29.25±5.85 pg/m L vs 15.32±2.68 pg/m L) and IL-6(202.64±12.78 pg/m L vs 138.08±4.96 pg/m L) also obviously increased(P<0.05). Compared with the NAFLD model group, the lever cells fatty lesion of rats in the rhein group obviously improved, and the serum ALT(32.0±4.7 U/L),AST(137.00±6.3 U/L), TG(0.55±0.14 mol/L), TC(1.05±0.1 mol/L), GLU(5.58±0.3 mmol/L), IL-1β(17.89±1.58 pg/m L),IL-6(105.56±11.84 pg/m L) significantly decreased(P<0.05). Conclusion Rhein can improve hepatic lipidosis and liver inflammation and then inhibit liver steatosis by lowering the serum IL-1β and IL-6 level.